Scenario wins: lewinke-thinking-bot* (26) SynapseSeer (19) laertes (3) Mantic (1) Panshul42 (1) tom_futuresearch_bot (1)
The question asks how many openFDA drug-enforcement records (distinct recall_numbers) will have report_date in the 12-report-week window 2026-05-26 through 2026-08-12 (observed after one extra indexing week). Forecasters agree the packet’s SERVER_ERROR likely reflected a malformed/escaped query rather than a true absence of records, and that the endpoint is updated weekly on Wednesday so the metric is a 12-week batch count (not a smooth daily arrival process); resolution waits to 2026-08-19 to allow indexing. Because no reliable in-window 2026 counts were available, teams anchored on FDA annual recalled-product totals (FY2020–FY2025) scaled to an ~11–12 week window, finding a mid/high-150s to low-160s center forecast (rough consensus ≈160 records). All groups emphasize strong overdispersion risk: single multi-product/multi-lot sterility, contamination, or CGMP clusters (as seen in 2023–24 ophthalmic recalls) can add many records and inflate the upper tail. One explicit probability split placed ≈18% on a low regime (≤130), ≈58% on 130–180, and ≈24% on ≥181; forecasters recommend using a negative-binomial/compound-Poisson model, pulling direct same-window analogs from prior years once the API query is fixed, and tracking weekly Wednesdays for sharp updates.
Forecast: Probability distribution:
We’re forecasting the count of openFDA drug enforcement records with report_date in 2026-05-26..2026-08-12 (a ~78–79 day window). Key quantitative anchors from the prompt:
Main modeling judgment: balance (i) historical summer slowdown (2024/2025 windows notably below their full-year daily rates), versus (ii) elevated recent 2026 cadence (181 in the immediately prior 78 days) that could partially persist due to ongoing lot expansions (e.g., Bisoprolol/HCTZ) and other enforcement currents. I treat 2024–2025 windows as a “seasonal floor” but not a direct forecast for 2026 because 2026’s recent pace is materially higher.
On the upside, there is a meaningful but not dominant chance the window exceeds 180 (open-above tail) from a moderate wave (e.g., accelerated lot-by-lot additions or compounding/GLP-1-related actions). I do not treat a 2022–2023 style outbreak wave (400+) as the central scenario; it remains a low-probability tail risk (captured only as part of the open-above bin in this market’s discretization).
Synthesis of the analysts:
My final distribution centers slightly below Forecaster 2’s median (to reflect seasonality/mean reversion) but well above 2024–2025 baselines (to reflect 2026’s elevated pace). I place a moderate (low-teens) probability into the open-above bin (≥181).
An amateur forecast would likely anchor on a single salient reference point (either the 2024–2025 window average ~128, or the immediately prior 78-day count ~181) and understate uncertainty about seasonality and episodic lot-expansion waves. My forecast explicitly blends: (1) a seasonal baseline from the same calendar window in recent quiet years, (2) 2026 YTD and most-recent-window run rates, and (3) a nontrivial but not overconfident open-above tail for wave scenarios. Confidence in improvement is moderate: the arithmetic anchors are strong, while the main residual uncertainty is whether a recall wave materializes during the window.
Forecast rationale (numeric):
— Iteration 1 — Across the forecasts, the core reasoning is that recent 2026 activity is the best anchor, but the outcome remains highly uncertain because FDA drug-enforcement records are event-driven and lot-level, so one large recall can create many records at once.
The collective reasoning points to a mid-160s outcome as most likely, with the main drivers being elevated 2026 enforcement pace and ongoing recall activity, offset by the possibility of a summer slowdown. The forecast remains wide and right-tailed because rare large recall events can sharply inflate the count.
— Iteration 2 — The overall forecast centers on a mid-150s to low-170s record count for the 5/26/2026–8/12/2026 window, with most of the reasoning built around three main ideas:
There is broad agreement that the distribution should be right-skewed because FDA drug enforcement records are counted lot-by-lot, meaning a single contamination or outbreak event can generate a very large number of records. That creates substantial upside tail risk, including the possibility of 400+ or even larger outcomes in exceptional cases.
Points of disagreement are mainly about how much weight to give the recent elevated 2026 pace versus the older 2024–2025 baseline. More conservative reasoning lands near the mid-150s, while more aggressive reasoning pushes toward ~170. The downside case is a quieter summer, possible indexing/reporting lag, or normalization after recent elevated activity.
Additional factors mentioned as potential modifiers include GLP-1 compounding-related regulatory activity as an upside source and FDA leadership transition as a possible source of short-term disruption or slowdown.
— Iteration 3 — Across the forecasts, the core reasoning is consistent: the expected number of FDA drug enforcement records for this window is likely to land in the mid-150s to mid-160s, with substantial upside risk from clustered recall activity.
The collective reasoning points to a moderately elevated but not extreme enforcement-record count: higher than recent summer comparables because 2026 has been active, yet constrained by the possibility that part of the recent surge is temporary. The main uncertainty is not the baseline trend, but whether the period includes a large clustered recall event, which could substantially lift the final count.
Question: How many drug enforcement records will the FDA publish with a report_date between 5/26/2026 and 8/12/2026? Final Prediction: Probability distribution:
Total Cost: extra_metadata_in_explanation is disabled Time Spent: extra_metadata_in_explanation is disabled LLMs: extra_metadata_in_explanation is disabled Bot Name: extra_metadata_in_explanation is disabled
Forecaster 1: Probability distribution:
Forecaster 2: Probability distribution:
Forecaster 3: Probability distribution:
The research compiles historical counts, year-to-date patterns, recent recall events, regulatory actions, and organizational factors to inform a forecast for the number of FDA drug enforcement records with report_dates between 5/26/2026 and 8/12/2026 (a 79-day window). Key data points include direct historical comparisons for the same calendar window (123 records in 2024, 133 in 2025, and much higher counts in 2022–2023 due to an artificial-tears outbreak), 2026 year-to-date totals through 5/24/2026 (292 records across 144 days, ≈2.03 records/day; recent 78-day window had 181 records ≈2.32/day), and several May 2026 recalls and ongoing multi-lot expansions (examples: children’s ibuprofen, naproxen oral solution, Nephronex multivitamin, and an expanding bisoprolol/hydrochlorothiazide lot-by-lot recall). The research also notes sector-level context (Sedgwick reported a Q1 2026 pharmaceutical recall-volume high) and regulatory/supply-chain actions (FDA proposals on excluding certain GLP-1 APIs from the 503B list, warning letters such as a May 21, 2026 letter to a Chinese API manufacturer).
The research enumerates factors that would push the count higher (recent elevated pace, Q1 2026 recall-volume peak, lot-by-lot recall additions) and factors that could reduce counts (FDA leadership turnover after Commissioner Marty Makary’s May 12, 2026 resignation, workforce reductions, near-term institutional uncertainty). It reports no active prediction markets for this specific enforcement-count question and provides quantitative anchor ranges used by the analyst (conservative baseline ~130–145, continuation-of-recent-pace ~165–183, central scenario ~145–165, outbreak tail >180), while listing key uncertainties (leadership transition effects, GLP-1 enforcement timing, outbreak risk, and lot-expansion dynamics).
Sources used or referenced in the supplied research (no direct URLs were provided with the research text; below are the named sources and relevant sites): Sedgwick Q1 2026 report; FDA enforcement records/openFDA drug enforcement API; FDA press releases and warning letters; news reports on FDA leadership changes (resignation of Marty Makary, acting commissioner Kyle Diamantas); FDA April 30, 2026 proposal regarding 503B/GLP-1 APIs; specific May 2026 recall notices (children’s ibuprofen, naproxen oral solution, a2 Milk infant formula, Nephronex multivitamin); bisoprolol/hydrochlorothiazide recall expansions; warning letter to Jixianglong (May 21, 2026); and prediction-market platforms checked (Metaculus, Manifold, Polymarket, Kalshi, Endpoint Arena). Relevant public webpages for these sources include: https://open.fda.gov/apis/drug/enforcement/ , https://www.fda.gov/news-events/press-announcements , https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters , https://www.sedgwick.com/ , https://www.metaculus.com , https://manifold.markets , https://polymarket.com , https://kalshi.com , https://endpointarena.com .
You’re forecasting the count of FDA drug enforcement records with report_dates in a 79-day window (May 26 - August 12, 2026). Based on my research, I found no active prediction markets for this specific question, but I’ve gathered comprehensive information on relevant trends, recent recalls, and historical base rates to inform your forecast.
According to Sedgwick’s Q1 2026 report (published May 14), the pharmaceutical sector recorded a 12-year high in recall volume with 218.8 million units impacted. Total recall events decreased 10.5% (877→785), but volume surged, reflecting “intensified regulatory pressure from the FDA.” This suggests quality control issues are generating significant enforcement activity.
Commissioner Marty Makary resigned May 12, 2026 after just over one year, following:
Kyle Diamantas (acting commissioner) now leads during this transition. The background information explicitly notes that Makary’s departure creates “near-term uncertainty about post-market surveillance priorities during the leadership-transition window.“ This could suppress enforcement record generation as the agency reorganizes.
On April 30, 2026, FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list, with:
However, warning letters and regulatory proposals don’t necessarily translate directly to openFDA drug enforcement records, which primarily track product recalls, not administrative actions.
These represent ongoing recall activity entering your forecast window.
The background information mentions the Bisoprolol Fumarate and Hydrochlorothiazide labeling recall (started 1/21/2026) has “continued to expand with lot-by-lot Enforcement Report additions.” This creates a steady stream of new records as additional lots are identified.
On May 21, 2026, the FDA issued a warning letter to Chinese pharmaceutical company Jixianglong for GLP-1 API violations, including falsifying production dates and CGMP violations. This highlights ongoing supply chain quality concerns that could generate future enforcement actions, though the timing is uncertain.
No prediction markets found for this specific question. I searched for:
This appears to be a specialized regulatory metric that hasn’t attracted prediction market attention, likely due to its technical nature and limited general interest.
Given the discrete range of 130-180 (with <130 clamped to 130, >180 in open upper tail):
The most critical judgment call is weighing the Q1 2026 “12-year high” recall volume against the May 12 commissioner resignation and its ripple effects on enforcement operations during your 79-day window.
Conditioning on non-annulment.
I think the critic’s third-round points are directionally right, and I am making a modest downward adjustment.
The most important valid criticism is that I was leaning a bit too hard on the “lot-by-lot expansion” upside story. FDA/openFDA definitions do support the idea that the counted unit is a recall/enforcement record with a recall_number, and that report_date/enforcementreportdt is the date FDA issued the Enforcement Report for that recalled product. But the same definitions also show that code_info can bundle many lots/serials inside a single record, so “many lots affected” does not mechanically imply “many new counted records.” (fda.gov)
I also accept the critic’s “mature historical data vs. real-time snapshot” point. The resolution freezes the openFDA query on August 19, 2026, one week after the report-date window closes. FDA/openFDA documentation says the dataset is updated weekly and that FDA can correct or change previously disclosed recall information, so fully settled 2024/2025 counts may be a slightly high-biased comparison to a near-real-time 2026 observation. (open.fda.gov) That does not make the old base rates useless, but it argues for shaving a little mass from the 181+ bin.
What I still defend: the weekly-report cadence correction remains real. This is not best modeled as a smooth 79-day Poisson flow; the window likely contains 12 weekly report dates in 2026 versus about 11 in the comparable 2024/2025 windows. That keeps the adjusted quiet baseline closer to 135–145 than the raw 123–133. And 2026’s direct openFDA record pace, as given in the prompt, is still materially hotter than those quiet baselines, so I do not want to pull the median all the way back toward 150.
My updated model is roughly:
The key scoring-relevant change is categorical: I now put P(181+) around 28–29%, down from roughly 30%+, and a median around 164 rather than 166. I still keep a fat right tail because historical artificial-tears-style years show that this metric can jump dramatically, but I am less eager to treat routine lot expansions as a strong upward force.
Updated prediction:
Percentile 0.1: 76
Percentile 1: 100
Percentile 5: 118.5
Percentile 10: 129.7
Percentile 20: 141.6
Percentile 30: 150.8
Percentile 40: 157.8
Percentile 50: 163.9
Percentile 60: 171.0
Percentile 70: 179.2
Percentile 80: 194.8
Percentile 90: 229
Percentile 95: 276
Percentile 99: 425
Percentile 99.9: 625
Conditioned on non-annulment.
I agree with the critic’s main correction: the weekly Enforcement Report cadence should be central. report_date is not a recall-initiation date; it is the date FDA issued the Enforcement Report for that product recall, and openFDA’s drug enforcement data are weekly Enforcement Report data. (fda.gov) That means the 2026 window likely has 12 report dates, versus 11 in the 2024 and 2025 same-calendar windows, so a raw 123/133 comparison is mechanically too low.
I also agree with the second critic that I should not overcorrect. The best base-rate anchor is not simply “2026 YTD per report × 12,” because summer windows in 2024–2025 were relatively thin, and the recent 181-in-78-days pace may contain transient lot-expansion effects. openFDA explicitly notes that recall information can later change or expand when firms discover more batches/lots are affected, so recent bursts are not necessarily stable process rates. (open.fda.gov)
The classification/posting-timing issue is a real downside mechanism. FDA says firms may initiate recalls before FDA completes classification and posts them, so records can miss the window if they are report-dated after August 12 even if the underlying recall activity began earlier. (fda.gov) However, since FDA also lists some “not yet classified” recalls to alert the public sooner, this timing risk is not as strong as if every record waited for full final classification. (fda.gov)
My revised synthesis:
Updated prediction:
Percentile 0.1: 84.4
Percentile 1: 104.4
Percentile 5: 120.4
Percentile 10: 131.0
Percentile 20: 142.4
Percentile 30: 151.4
Percentile 40: 158.4
Percentile 50: 165.4
Percentile 60: 172.4
Percentile 70: 180.4
Percentile 80: 196.4
Percentile 90: 224.4
Percentile 95: 276.4
Percentile 99: 425.4
Percentile 99.9: 610.4
Conditioning on non-annulment.
I largely accept the critic’s third-round adjustment. The weekly-report structure remains the key correction: this endpoint is not a smooth daily process, since openFDA’s drug enforcement records come from FDA’s Recall Enterprise System, are updated weekly, and include classified recalls in the weekly Enforcement Report; the FDA definition of the enforcement-report date is likewise the date FDA issued the weekly report for the product recall. (open.fda.gov)
What I’m updating on:
I still do not want to move all the way back to a low-150s median. The YTD and recent openFDA record pace are materially elevated, and the window has an extra expected weekly report date relative to 2024/2025. Also, because one moderate multi-lot recall can add dozens of records, the 181+ open upper bin remains very live. My current best estimate is roughly:
So I’m making a modest downward adjustment from my prior median of 166.8 to about 165, with a slightly fatter low tail and a slightly lighter 180–220 region.
Updated prediction:
Percentile 0.1: 84
Percentile 1: 103
Percentile 5: 120.5
Percentile 10: 130.4
Percentile 20: 143
Percentile 30: 151.2
Percentile 40: 158.2
Percentile 50: 164.8
Percentile 60: 171.8
Percentile 70: 179.6
Percentile 80: 193.5
Percentile 90: 216.5
Percentile 95: 249.5
Percentile 99: 410.5
Percentile 99.9: 560.5
Modal: Below 130 (15.0%) • partial_shift • 6m25s
Reading: strict
The resolution criteria are highly specific and mechanical: a single API query URL, a named JSON field (
meta.results.total), a precise observation timestamp (12:00 UTC on 2026-08-19), and explicit rules for every edge case including zero results, fallback sources, and annulment conditions. There is essentially no room for interpretive latitude — the resolver follows a deterministic procedure with no subjective judgment required under normal conditions.
Total evidence registered (shared pool): ?
| Variant | Perspective | Model | Turns | Tools | Status |
|---|---|---|---|---|---|
| 0 | inside_view (inside_view_v1) | anthropic/claude-sonnet-4-6 | 25 | 41 | OK |
| 1 | outside_view (outside_view_v1) | anthropic/claude-sonnet-4-6 | 25 | 37 | OK |
| 2 | contrarian (contrarian_v1) | anthropic/claude-sonnet-4-6 | 25 | 40 | OK |
Evidence confidence: medium
high evidence]The recent 78-day rate of 2.32/day continues into the window; ongoing multi-lot recalls (Bisoprolol, any new large event) sustain the elevated pace; FDA enforcement continues despite staffing cuts; no single catastrophic outbreak but consistent moderate recall volume.
Leadership vacuum post-Makary and DOGE staffing reductions slow recall processing; the recent elevated rate was driven by specific transient events (Bisoprolol lot-by-lot additions, Gold Star residual) that fully resolve before or early in the window.
medium evidence]The 5/26–8/12 summer window historically underperforms the annual average in non-outbreak years (123 in 2024, 133 in 2025); DOGE staffing cuts reduce inspection capacity and recall initiation rate; leadership transition slows enforcement priorities; recent elevated YTD rate was driven by transient events that dissipate by window start.
The 2026 YTD rate (~2.03/day) already exceeds both 2024 and 2025 annual averages; baseline projection’s mean (132) sits near or below the resolution grid floor; ongoing multi-lot recall activity suggests rates won’t revert sharply.
medium evidence]The full 2026 YTD rate of 2.03/day (rather than the recent elevated 2.32/day or the historical summer baseline) applies; represents a middle path where the transient Bisoprolol/Gold Star contribution fades but overall enforcement pace remains above 2024–2025 levels.
Rate assumptions are contested — recent 78-day rate (2.32/day) and summer-window historical underperformance pull in opposite directions; this scenario requires precise rate stabilization at an intermediate level.
low evidence]A major contamination event analogous to 2022–2023 artificial tears outbreak triggers multi-lot recall waves; finalization of 503B GLP-1 exclusion rule triggers a wave of compounding facility enforcement actions converting to recalls; a large multi-product facility recall (like Gold Star) occurs within the window.
2024 and 2025 non-outbreak summers show no outbreak occurred in either year; 503B GLP-1 final rule had not issued as of evidence cutoff (June 2026) and rule finalization does not directly generate recall records immediately; the artificial-tears-scale event is rare and idiosyncratic.
inside_view_v1)Inside-View Causal Analysis
Current state → causal chain → outcome:
The window is 78 days (5/26/2026–8/12/2026). The key causal question is: which arrival rate governs?
Three rate anchors from the brief:
- Recent 78-day rate (3/7–5/24/2026): 181 records = 2.32/day → arrival projection mean≈179, median≈173 (source 21) — tagged
relative_evidence_strength: high- 2026 YTD rate: 2.03/day → arrival projection mean≈158, median≈148 (source 30) — tagged
medium- Historical non-outbreak summer baseline: ~1.66/day → mean≈132, median≈128 (source 24) — tagged
medium- Outbreak scenario (181+): tagged
lowWeighting by evidence strength tags:
- The
high-evidence scenario (recent-rate continuation, 155–180) carries substantially more mass.- The two
mediumscenarios (summer baseline reversion 120–140, and YTD moderate 140–165) share moderate mass.- The
lowscenario (outbreak/surge 181+) gets minimal mass.Inside-view causal reasoning:
The recent 78-day rate (2.32/day) is the most causally proximate signal. It reflects actual enforcement activity in the system as of late May 2026. However, two countervailing forces push against simple extrapolation:
Summer seasonality: Historical non-outbreak summers (2024=123, 2025=133) show the May–August window consistently underperforms annual averages. This is a real pattern — summer windows ran ~16–18% below annual per-78-day pace in 2024–2025.
Transient inflators: The Bisoprolol lot-by-lot expansion and Gold Star residual likely inflated the Q1-early Q2 2026 rate. As these wind down, the rate should partially revert toward the YTD average (~2.03/day).
DOGE cuts: ~3,500 FDA staff cut, 170 inspection staff — this should modestly suppress recall initiation rates, pulling toward the lower scenarios. Post-Makary leadership vacuum reinforces this.
2026 structural shift: Despite DOGE cuts, 2026 YTD rate (~2.03/day) still exceeds 2024 average (1.80/day) and approaches 2025 (~2.10/day), suggesting an elevated enforcement environment. Warning letters up 59% in FY2025.
My inside-view synthesis:
The causal mechanism is: elevated-but-declining recent rate → summer seasonal underperformance → partial DOGE suppression → landing somewhere between 130–175, with central tendency around 145–165.
The
high-evidence recent-rate scenario anchors to 155–180. But summer seasonality + transient factors fading means I expect a modest downward adjustment from that scenario’s center. I weight the YTD-moderate scenario (140–165) heavily alongside the recent-rate scenario.Distribution shape:
- Bins 0 (below 130): ~10% — summer reversion to 2024-2025 levels; DOGE reducing enforcement
- Bins 1-3 (130–149): ~25% — partial reversion territory, non-outbreak summer floor
- Bins 4-6 (149–168): ~40% — most mass, consistent with elevated 2026 pace moderated by summer patterns
- Bins 7-8 (168–180): ~12% — upper end of recent-rate scenario
- Bin 9 (180+): ~13% — recent-rate model p75≈214 shows real upper tail probability; outbreak scenario low-evidence but non-trivial
Bin-by-bin allocation:
- below 130 (bin_0): 0.10
- 130–136 (bin_1): 0.07
- 136–143 (bin_2): 0.09
- 143–149 (bin_3): 0.10
- 149–155 (bin_4): 0.12
- 155–161 (bin_5): 0.12
- 161–168 (bin_6): 0.12
- 168–174 (bin_7): 0.09
- 174–180 (bin_8): 0.06
- above 180 (bin_9): 0.13
Sum = 1.00. The distribution is roughly bimodal — peaked around 149–168 (reflecting the high-evidence recent-rate scenario moderated by seasonal effects) with meaningful tails reflecting the genuine uncertainty between the three rate models.
outside_view_v1)Reference class: historical same 78-day summer windows in non-outbreak years (the brief gives 2024=123 and 2025=133 for the 5/26–8/12 window; average ≈128). Base rate: ~128 records for the window (non-outbreak summers) — i.e., centered below the question’s 130 floor (brief: historical same-window counts 123 and 133). Adjustment: +~25 percentage points of probability mass toward higher bins because the brief documents a materially elevated very-recent arrival rate (181 records over the most recent 78-day period → ≈2.32/day) and a computed arrival-process projection with mean≈179 under that recent rate (brief sources: recent 78‑day =181 records; arrival projection mean≈179, median≈173, p25≈137, p75≈214; scenario 1 in the brief was tagged high evidence). Also offsetting forces (DOGE staffing cuts, leadership transition, and historical summer underperformance) are reported in the brief (brief: ~3,500 FDA cuts incl. ~170 inspection staff; Makary resignation) and argue for some pullback toward the non-outbreak baseline. Because the brief contains a strong quantitative arrival projection (treated as strong evidence) I shift the outside-view away from the pure historical baseline but conservatively — keeping most mass in the mid-range rather than the extreme upper tail. Confidence-in-evidence: medium (the brief states medium), so I moderately widen the distribution to reflect uncertainty (noting the brief’s explicit low-evidence outbreak scenario). Final: the probability distribution above places most mass in the central bins (143–161) consistent with the brief’s middle-path and recent-rate projections while preserving modest probability for reversion to the non-outbreak baseline (bin_0–bin_2) and a small tail for a surge/outbreak (bin_9). Specific mapping decisions: - I concentrated probability in bins 3–6 (143–168) because the brief’s quantitative projections (YTD-rate mean≈158; recent-rate mean≈179) and the “YTD-2026 moderate” and “recent-rate continuation” scenarios (one tagged high evidence, one medium) make the mid-to-upper part of the 130–180 grid the most plausible outside-view outcome. - I left non-negligible mass (≈0.06) on Below-130 to reflect the historical non-outbreak baseline (2024–2025) and because the question’s floor clamps ≤130 to the lowest in-range bin. - I put a small (~0.03) probability on the open upper tail (Above 180) to reflect the low-probability but high-impact outbreak/surge scenario the brief documents (2022 and 2023 windows were 428 and 434 in outbreak years) and the brief’s explicit warning that a single large contamination event could produce that outcome. Inline brief facts used: historical same-window counts 2024=123 and 2025=133; recent 78-day count =181 (≈2.32/day); computed arrival projections: recent-rate mean≈179 (p25≈137, p75≈214) and YTD-rate mean≈158 (p25≈106, p75≈199); DOGE staffing cuts (~3,500 employees incl. ~170 inspection staff) and Commissioner Makary’s May 2026 resignation; confidence_in_evidence=medium. Reading: strict (the brief’s interpretation labeled the resolution rules strict; I rely on the exact openFDA query and timing specified in the brief).
contrarian_v2)Adversarial reading
The implicit consensus in the brief pulls toward the 130–180 range (especially 140–180), anchored on the high-evidence recent-rate scenario (2.32/day yielding mean ≈179) and the medium-evidence YTD-rate scenario (mean ≈158), while assigning only low weight to the outbreak tail and medium weight to the low historical-summer baseline.
Counter-evidence found (or absence)
DOGE cuts removed 170 inspection/investigations staff and created a leadership vacuum after Makary’s May 12 resignation; these factors directly impair the inspection-to-recall pipeline that generated the recent elevated rate, and historical non-outbreak summers (2024=123, 2025=133) already sit below the recent-rate projection. The recent 78-day run-rate may therefore be an upward-biased transient rather than a new structural level.
Distribution implications
The adversarial reading therefore shifts material probability mass leftward into Below 130 (bin_0) and the lower in-range bins relative to a naive recent-rate-weighted consensus, while trimming the upper tail (bin_9) because the same staffing and leadership frictions make an artificial-tears-scale surge even less likely than the brief’s low-evidence tag already implies.
Strategy: logit_mean • Drafts: 3/3
anchoring_v1The draft rationale explicitly anchors its central tendency to the “most recent 78-day rate” (2.32/day, yielding mean≈179), treating it as the p50-equivalent anchor and tagging it “high” evidence — but this is precisely the anchoring error: it uses the most optimistic (highest) of the three available rate estimates as the modal scenario rather than the median expectation across scenarios. The brief’s own non-outbreak summer baseline (mean≈132, historical 2024=123, 2025=133) and the YTD rate (mean≈158) are both tagged medium evidence, yet the recent rate is elevated by explicitly transient events (Bisoprolol lot-by-lot additions, Gold Star residual). A flat-prior synthesis across the three rate models would place the modal expectation closer to 150–160, not 173. Furthermore, the draft places ~10.7% in below 130 (bin_0) — consistent with “summer reversion” — yet places the same ~10.7% in an asymmetrically small below-median zone while the upper tail (bins 7–9 combined: ~21%) is inflated relative to a truly centered estimate. The correct anchor should weight all three rate models more evenly, shifting the modal bin toward 143–161 rather than 149–168.
ceiling_v1The critical structural constraint the forecaster partially missed is the monotone floor imposed by the window start date coinciding with the forecast date. The brief states “Today’s date is 2026-05-27” and the window begins 5/26/2026 — meaning at least one day’s worth of records (approximately 2 records) already exist in the window at forecast time, establishing a trivial but real floor. More importantly, the brief explicitly states the historical non-outbreak same-window counts were 123 (2024) and 133 (2025), both below the question’s stated bin_0 floor of 130. This means the two most recent directly comparable historical data points would have resolved in clamped to 130 (bin_0), yet the draft assigns only ~10.7% to bin_0. The structural constraint here is: absent a material rate elevation above those non-outbreak summers, the probability of landing at or below 130 should be substantially higher. Additionally, the brief’s seasonal constraint is strong: non-outbreak summers systematically run 16–18% below annual averages, and the question window (May–August) coincides precisely with this underperformance pattern. The 2026 YTD rate of 2.03/day × 78 days = 158 expected, but conditioned on summer seasonal depression (~16% below annual pace), the seasonally-adjusted expectation drops to ~133 — squarely in bin_0 territory. The draft’s ~40% mass in bins 4–6 (149–168) appears over-weighted relative to these structural seasonal constraints.
math_v1The draft forecast distribution sums to 1.00012 (exceeds tolerance by ~0.01) and exhibits a structural inconsistency: the rationale cites three arrival projections with means of 179, 158, and 132, yet the published distribution places only ~0.21 of probability mass below 143 (bin_0 through bin_2) despite acknowledging two medium-evidence scenarios with p25 values at 106 and 101. The distribution’s mode (bins 4–5: 149–161, ~0.25 cumulative) sits 16–27 points above the baseline scenario’s median (128), creating an asymmetry that contradicts the stated “central tendency around 145–165” without explicit justification for why the YTD scenario (mean=158) should dominate the non-outbreak baseline (mean=132) when both are tagged medium evidence.
Reviews consumed: 3
All three reviewers converged on a shift_lower direction: the anchoring reviewer flagged that the draft over-weighted the recent 78-day rate (2.32/day, mean≈179) as the central anchor when transient inflators (Bisoprolol, Gold Star) likely dissipate; the ceiling reviewer emphasized the strong seasonal structural constraint—2024 (123) and 2025 (133) non-outbreak summer windows both sat at or below bin_0, suggesting bin_0 deserves substantially more mass; the math reviewer flagged that the draft sums to >1.0 and that scenario weighting was internally inconsistent (medium-evidence baseline scenario with p25≈101 should imply more bin_0 mass). I accepted the seasonal-conditioning argument as the strongest: the recent rate is a spring rate applied to a structurally depressed summer window. I shifted mass from bins 5-8 down into bins 0-3, raising bin_0 from ~0.107 to ~0.15 to reflect the historical floor pattern. I partially accepted the math reviewer’s upper-tail concern: the recent-rate p75≈214 warrants meaningful bin_9 mass even after seasonal adjustment, so I kept bin_9 near 0.07 rather than dropping it further. The contrarian draft’s argument that DOGE cuts impair the outbreak pipeline (supporting trimmed upper tail) was already partly reflected; I did not fully adopt the ceiling reviewer’s 0.17 bin_0 because the 2026 YTD rate (2.03/day) does meaningfully exceed the 2024 baseline (1.80/day), supporting some structural elevation.
[ceiling] Bin_0 should hold ~0.17 given that 2024 (123) and 2025 (133) both resolved at/below 130
[math] Upper tail bin_9 should be ~0.15-0.20 given recent-rate p90≈256
| Bin | Probability |
|---|---|
| Below 130 (bin_0) | 15.0% |
| 130-136 (bin_1) | 11.0% |
| 136-143 (bin_2) | 12.0% |
| 143-149 (bin_3) | 12.0% |
| 149-155 (bin_4) | 12.0% |
| 155-161 (bin_5) | 10.0% |
| 161-168 (bin_6) | 9.0% |
| 168-174 (bin_7) | 7.0% |
| 174-180 (bin_8) | 5.0% |
| Above 180 (bin_9) | 7.0% |
wooley_rhino • run 7e390708 • $3.08 • 6m25s
Weekly reporting cadence and per-lot recordization cap the short-term variance in published counts.
A sustained low regime in recent years lowers the baseline relative to the long-run mean.
Through late May the pace is higher than 2024–2025 but shows no single, already-visible mega-wave.
Classification mix and top-firm clustering create pockets of concentration without an overwhelming dominant source.
A small number of multi-lot recalls could produce sharp upward jumps across the twelve scheduled reports.
If no new contamination or compounding episodes occur, the extra weekly report will likely produce only a modest lift over the low baseline.
The largest unresolved risks are timing and scale of latent cluster recalls and regulatory-driven surges tied to GLP‑1 and compounding enforcement.
Indexing delays and late-added lot records leave a residual tail of uncertainty around the final published total.
Median forecast: 153 records
Historical baseline anchors the center. The same 78-day window in 2024 and 2025 produced 123 and 133 records respectively. Both years ran 15–20% below annual averages during summer months, establishing a seasonal pattern. This non-outbreak baseline (mean ~128) is the strongest reference point.
2026 shows mixed signals. Year-to-date enforcement is running ~61 records/month, modestly above 2024–2025 rates. However, April’s spike to 100 records appears transient—May 1–24 collapsed to only 32 records (~40/month annualized), suggesting the April cluster has largely passed. This argues for modest upward adjustment from the 2024–2025 baseline but not a step-change.
Known enforcement pipelines provide incremental upside. Ongoing multi-lot recalls (Bisoprolol Fumarate+HCTZ, Fresenius Kabi/Teva/Fagron sterile injectables) and GLP-1 compounding enforcement (30 warning letters issued in March) could add 20–60 records if facilities initiate formal recalls in-window. These are identified but uncertain in timing and volume.
Outbreak risk creates a fat right tail. Historical same-window counts in 2021–2023 ranged from 316–434 during contamination events (e.g., artificial tears outbreak). No analogous outbreak is currently known, but sterile compounding violations remain active. Estimated ~10% probability of a major event pushing the outcome above 250.
Seasonal and leadership headwinds are modest. Summer historically suppresses enforcement below annual average, and FDA leadership transition creates minor uncertainty. These factors are already embedded in the 2024–2025 baseline
Forecast (percentiles, aggregated):
Per-model forecasts:
Rationale: Summary The forecast for the number of FDA drug enforcement records published between May 26, 2026, and August 12, 2026, centers on an estimate of 150 records, with a 10th to 90th percentile range of 128 to 191. Historical totals for this exact 79-day summer window display significant variance, driven primarily by single-event mass recalls. While recent non-outbreak years like 2024 and 2025 yielded lower counts of 123 and 133 records respectively, the pace in early 2026 has been elevated. By late May 2026, the FDA had published 292 records year-to-date, averaging roughly 2.0 records per day. However, this year-to-date average obscures substantial month-to-month volatility. A notable spike in April (100 records) pushed the average up, but the pace moderated significantly in May back to approximately 1.6 records per day. Extrapolating the baseline rates seen in the most recent non-outbreak years, along with the historical trend of a summer slowdown in enforcement publications, suggests a baseline of 130 to 140 records. Despite this baseline, the distribution is distinctly right-skewed due to several active enforcement currents. Ongoing recalls, particularly lot-by-lot additions for Bisoprolol Fumarate and Hydrochlorothiazide, and targeted crackdowns on compounded GLP-1 products elevate the baseline. Balancing the recent moderation in May and the historical summer slowdown against these specific enforcement catalysts results in a median estimate of 150 records, leaving a long upper tail to account for the possibility of batch-heavy enforcement waves.
Strongest Arguments for Higher Values
Strongest Arguments for Lower Values
Key Uncertainties
How many drug enforcement records will the FDA publish with a report_date between 5/26/2026 and 8/12/2026?
Key figures
Historical context
The FDA Drug Enforcement Report volume is highly sensitive to “mass recall” events, where a single quality issue affects dozens or hundreds of product lots. Historically, the May 26 to August 12 window has shown extreme variance. In 2022 and 2023, the window saw 428 and 434 records respectively, driven almost entirely by a major bacterial contamination outbreak in artificial tears (ophthalmic products) involving brands like EzriCare and Apotex. These years represent “outbreak peaks.” In contrast, 2024 (123 records) and 2025 (133 records) represent “non-outbreak baselines.” The current 2026 environment appears to be operating at a mid-tier level—higher than the 2024/2025 baseline due to intensified oversight of the GLP-1 (weight loss) market and labeling corrections, but without the massive contamination events that defined the 2022-2023 period. As of May 24, 2026, the year-to-date average of ~2.03 records per day is significantly higher than the ~1.58 records per day seen in 2024.
Tailwinds
Headwinds
Detailed reasoning
To arrive at the prediction of 157.5 records, I conducted a dual-track analysis focusing on historical seasonal baselines and the high-frequency run-rate observed in early 2026.
First, I established the historical floor. In 2024 and 2025, which were considered “non-outbreak” years, the May 26 to August 12 window saw 123 and 133 records, respectively. This gives a seasonal baseline average of approximately 128 records. However, 2026 has consistently outperformed these years in terms of enforcement volume. As of May 24, 2026, the FDA has published 292 records over 144 days. Extrapolating this daily rate of 2.03 records across the upcoming 79-day window yields an expected value of 160 records.
Second, I analyzed recent acceleration. The 78-day period immediately preceding this window (March 7 to May 24) saw a significant jump to 181 records (2.32 per day). This acceleration is largely attributed to specific “currents,” most notably the expansion of the Bisoprolol Fumarate labeling recall and a concerted crackdown on the GLP-1 compounding sector. If this higher pace continues, the window would likely exceed 183 records.
Third, I considered the impact of structural changes. The resignation of Commissioner Marty Makary and the appointment of Kyle Diamantas as acting commissioner introduces a high degree of administrative uncertainty. While reforms initiated under Makary are intended to “move forward,” leadership transitions often result in temporary processing bottlenecks. Furthermore, the decline in N-nitrosamine recalls relative to the 2023-2024 peak acts as a downward pressure on the “base” volume of recalls.
I weighted the 2026 YTD average (160) most heavily but adjusted the “most likely” value slightly downward to 157.5 to account for potential administrative slowdowns and the absence of a visible “mass outbreak” like those seen in 2022. The 50% HDI (147.5 to 167.5) captures the most probable range of “lumpy” weekly reporting, while the wider 80% interval accounts for the possibility of either a reversion to the 2025 baseline or a moderate surge in GLP-1-related enforcement actions. I discounted the extreme 400+ record outliers from 2022-2023 as they required a specific multi-manufacturer contamination event that has not yet materialized in the 2026 data.
Key uncertainties
Conclusion